No connection

Search Results

ABBV vs ABUS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ABUS
Arbutus Biopharma Corporation
BEARISH
Price
$4.53
Market Cap
$872.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
ABUS
--
Forward P/E
ABBV
15.42
ABUS
-27.41
P/B Ratio
ABBV
-146.66
ABUS
11.38
P/S Ratio
ABBV
6.5
ABUS
61.92
EV/EBITDA
ABBV
15.27
ABUS
-29.91

Profitability

Gross Margin
ABBV
71.46%
ABUS
-79.23%
Operating Margin
ABBV
35.5%
ABUS
-727.31%
Profit Margin
ABBV
4.0%
ABUS
-237.88%
ROE
ABBV
137.96%
ABUS
-38.52%
ROA
ABBV
9.59%
ABUS
-14.94%

Growth

Revenue Growth
ABBV
9.1%
ABUS
-33.2%
Earnings Growth
ABBV
-88.7%
ABUS
--

Financial Health

Debt/Equity
ABBV
--
ABUS
0.05
Current Ratio
ABBV
0.72
ABUS
15.73
Quick Ratio
ABBV
0.47
ABUS
15.52

Dividends

Dividend Yield
ABBV
3.05%
ABUS
--
Payout Ratio
ABBV
490.15%
ABUS
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ABUS BEARISH

ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.

Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability

Compare Another Pair

ABBV vs ABUS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Arbutus Biopharma Corporation (ABUS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile